The potential role of mTOR inhibitors in the treatment of endocrine tumors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The potential role of mTOR inhibitors in the treatment of endocrine tumors
Authors
Keywords
-
Journal
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
Volume 33, Issue 4, Pages 276-281
Publisher
Springer Nature
Online
2014-03-22
DOI
10.1007/bf03345792
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells
- (2010) V. Cerovac et al. CANCER RESEARCH
- Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro
- (2009) Alexander Gorshtein et al. ENDOCRINE-RELATED CANCER
- Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors
- (2009) D Dworakowska et al. ENDOCRINE-RELATED CANCER
- Role of the Novel mTOR Inhibitor RAD001 (Everolimus) in Anaplastic Thyroid Cancer
- (2009) C. Papewalis et al. HORMONE AND METABOLIC RESEARCH
- Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)
- (2009) M. R. Druce et al. HORMONE AND METABOLIC RESEARCH
- Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
- (2009) I. Okamoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Dual Inhibition of Mitogen-Activated Protein Kinase Kinase and Mammalian Target of Rapamycin in Differentiated and Anaplastic Thyroid Cancer
- (2009) Ning Jin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas
- (2009) Maria Chiara Zatelli et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
- (2009) RuiRong Yuan et al. Journal of Hematology & Oncology
- The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt–mTOR–p70S6K pathway in human medullary thyroid carcinoma cells
- (2009) Simona Grozinsky-Glasberg et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Aging — Lost in Translation?
- (2009) Pankaj Kapahi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
- (2008) A. Moreno et al. ENDOCRINE-RELATED CANCER
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line
- (2007) Simona Grozinsky-Glasberg et al. NEUROENDOCRINOLOGY
- Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
- (2007) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now